RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Apple Turns 50: From Garage Startup to AI Crossroads 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
SYDNEY, Australia, July 16, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced it will receive a second undisclosed significant clinical milestone payment from Novartis, based on the collaboration and licensing agreement between the companies, relating to Prima’s IMP701 LAG-3 antibody (also referred to as LAG525).
The LAG525 antibody is currently being evaluated in clinical trials together with Novartis’ PD1 inhibitor PDR001 for the treatment of cancer. Novartis has full responsibility for the continued development of the antibody program and Prima is eligible to receive further potential development-based milestone payments and royalties on sales following commercialisation of the products.
Mr. Marc Voigt, CEO of Prima, commented, "We are very pleased by the progression of the LAG525 program. It is wonderful to see our commercial partners continuing to progress the development of LAG-3 products. This announcement, together with the other clinical and non-clinical data published regarding other LAG-3 directed drug development programs over the past twelve months is very encouraging."
About IMP701
IMP701 is a therapeutic antibody originally developed by Immutep S.A.S to target LAG-3. This antagonist antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg). The antibody works to both activate effector T cells (by blocking inhibitory signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevent T cells from responding to antigen stimulation. The antibody therefore removes two brakes that prevent the immune system from responding to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T cell pathway and don’t address the Treg pathway.
IMP701 was licensed to CoStim Pharmaceuticals in 2012 which was subsequently acquired by Novartis in 2014.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: Australian Investors/Media: Mr Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected] U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected]
